Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-TRD2206 is an investigational radiopharmaceutical PET tracer designed to target **Nectin-4** (Poliovirus receptor-related protein 4). Developed by the **Affiliated Hospital of North Sichuan Medical College**, the agent consists of the positron-emitting radioisotope Copper-64 (64Cu) conjugated to the TRD2206 targeting moiety. It is primarily utilized in molecular imaging to non-invasively assess Nectin-4 expression levels in various malignant solid tumors, including urothelial, esophageal, and cervical carcinomas. By providing a visual and quantitative map of Nectin-4 density, 64Cu-TRD2206 is intended to assist in patient stratification for Nectin-4-targeted therapies, such as antibody-drug conjugates, and to monitor treatment response in clinical settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 64Cu-TRD2206.